ERBB2 and breast cancer: Next, we performed ESTIMATE (Estimation of STromal and Immune cells in MAlignant Tumors using Expression data) analyses24 to infer the presence of infiltrating stromal and immune cells in two independent cohorts of HER2+ BC patients treated with trastuzumab.